UTRS
Minerva Surgical, Inc. [UTRS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
UTRS Stock Summary
In the News
UTRS Financial details
Company Rating
Neutral
Market Cap
5.77M
Income
-35.55M
Revenue
51.69M
Book val./share
2.28
Cash/share
1.25
Dividend
-
Dividend %
-
Employees
174
Optionable
No
Shortable
Yes
Earnings
30 Apr 2024
P/E
-0.27
Forward P/E
-
PEG
0.03
P/S
0.19
P/B
0.48
P/C
0.37
P/FCF
-0.25
Quick Ratio
0.88
Current Ratio
1.88
Debt / Equity
2.15
LT Debt / Equity
1.54
-
-
EPS (TTM)
-4.81
EPS next Y
-
EPS next Q
-
EPS this Y
-61.32%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-10.65%
EPS Q/Q
-17.35%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-50%
Inst Own
19.73%
Inst Trans
0.51%
ROA
-49%
ROE
-145%
ROC
-0.57%
Gross Margin
54%
Oper. Margin
-57%
Profit Margin
-69%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.325-14.0
52W High
-
52W Low
-
RSI
47
Rel Volume
2.7
Avg Volume
2.72K
Volume
7.33K
Perf Week
-29.23%
Perf Month
-24.59%
Perf Quarter
-84.72%
Perf Half Y
-84.72%
-
-
-
-
Beta
0.682
-
-
Volatility
0.33%, 0.17%
Prev Close
-68.92%
Price
0.46
Change
-17.12%
UTRS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 28.06 | 37.03 | 148.61 | 34.92 | |
| Net income per share | -75.29 | -17.91 | -61.22 | -23.68 | |
| Operating cash flow per share | -21.35 | -12 | -63.83 | -24.69 | |
| Free cash flow per share | -21.59 | -12.45 | -65.49 | -24.74 | |
| Cash per share | 29.22 | 17.02 | 115.82 | 4.82 | |
| Book value per share | -220.62 | -217.47 | 125.79 | 11.93 | |
| Tangible book value per share | -220.62 | -259.77 | 26.05 | -6.66 | |
| Share holders equity per share | -220.62 | -217.47 | 125.79 | 11.93 | |
| Interest debt per share | 100.83 | 107.29 | 146.01 | 29.79 | |
| Market cap | 166.87M | 183.59M | 36.04M | 6.42M | |
| Enterprise value | 215.67M | 263.52M | 34.71M | 39.17M | |
| P/E ratio | -2.39 | -10.05 | -1.68 | -0.19 | |
| Price to sales ratio | 6.41 | 4.86 | 0.69 | 0.13 | |
| POCF ratio | -8.43 | -15 | -1.61 | -0.18 | |
| PFCF ratio | -8.34 | -14.46 | -1.57 | -0.18 | |
| P/B Ratio | -0.82 | -0.83 | 0.82 | 0.37 | |
| PTB ratio | -0.82 | -0.83 | 0.82 | 0.37 | |
| EV to sales | 8.29 | 6.98 | 0.67 | 0.78 | |
| Enterprise value over EBITDA | -12.22 | -32.29 | -1.84 | -1.27 | |
| EV to operating cash flow | -10.9 | -21.53 | -1.55 | -1.1 | |
| EV to free cash flow | -10.78 | -20.76 | -1.51 | -1.1 | |
| Earnings yield | -0.42 | -0.1 | -0.6 | -5.31 | |
| Free cash flow yield | -0.12 | -0.07 | -0.64 | -5.55 | |
| Debt to equity | -0.37 | -0.44 | 0.89 | 2.31 | |
| Debt to assets | 1.63 | 1.06 | 0.34 | 0.58 | |
| Net debt to EBITDA | -2.76 | -9.79 | 0.07 | -1.06 | |
| Current ratio | 2.88 | 1.37 | 3.32 | 2.53 | |
| Interest coverage | -1.12 | -1.27 | -2.49 | -9.59 | |
| Income quality | 0.38 | 0.67 | 1.04 | 1.04 | |
| Dividend Yield | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.32 | 0.22 | 0.43 | 0.29 | |
| Research and developement to revenue | 0.04 | 0.09 | 0.1 | 0.11 | |
| Intangibles to total assets | 0 | 0.47 | 0.3 | 0.39 | |
| Capex to operating cash flow | 0.01 | 0.04 | 0.03 | 0 | |
| Capex to revenue | -0.01 | -0.01 | -0.01 | 0 | |
| Capex to depreciation | -0.13 | -0.06 | -0.05 | -0.01 | |
| Stock based compensation to revenue | 0.02 | 0.02 | 0.13 | 0.14 | |
| Graham number | 611.34 | 296 | 416.26 | 79.72 | |
| ROIC | 0.2 | 0.12 | -0.35 | -0.54 | |
| Return on tangible assets | -1.5 | -0.37 | -0.27 | -0.81 | |
| Graham Net | -236.01 | -279.53 | -48.69 | -21.47 | |
| Working capital | 28.59M | 12.15M | 52.38M | 21.84M | |
| Tangible asset value | -204.52M | -264.95M | 9.13M | -9.6M | |
| Net current asset value | -207.39M | -268.44M | 4.02M | -15.6M | |
| Invested capital | -0.37 | -0.44 | 0.89 | 2.31 | |
| Average receivables | 0 | 6.16M | 7.84M | 7.27M | |
| Average payables | 0 | 3.85M | 3.57M | 3.22M | |
| Average inventory | 0 | 7.47M | 12.94M | 16.27M | |
| Days sales outstanding | 55.38 | 80.98 | 51.08 | 52.57 | |
| Days payables outstanding | 107.72 | 68.62 | 61.38 | 44.4 | |
| Days of inventory on hand | 121.88 | 199.67 | 265.24 | 266.8 | |
| Receivables turnover | 6.59 | 4.51 | 7.15 | 6.94 | |
| Payables turnover | 3.39 | 5.32 | 5.95 | 8.22 | |
| Inventory turnover | 2.99 | 1.83 | 1.38 | 1.37 | |
| ROE | 0.34 | 0.08 | -0.49 | -1.99 | |
| Capex per share | -0.24 | -0.44 | -1.67 | -0.05 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 8.8 | 0.47 | 2.62 | 1.51 | 1.35 | |
| Net income per share | -8.5 | -0.21 | -2.81 | -0.98 | -0.81 | |
| Operating cash flow per share | -4.76 | -0.53 | -1.75 | -1.09 | -0.57 | |
| Free cash flow per share | -4.76 | -0.53 | -1.77 | -1.09 | -0.58 | |
| Cash per share | 10.57 | 0.23 | 5.28 | 1.78 | 1.25 | |
| Book value per share | 15.06 | 0.58 | 7.13 | 3 | 2.28 | |
| Tangible book value per share | -5.14 | -0.32 | 1.95 | 0.38 | -0.23 | |
| Share holders equity per share | 15.06 | 0.58 | 7.13 | 3 | 2.28 | |
| Interest debt per share | 28.46 | 1.38 | 8.5 | 5.06 | 4.78 | |
| Market cap | 22.74M | 131.89M | 21.03M | 45.31M | 29.28M | |
| Enterprise value | 47.46M | 164.64M | 35.31M | 73.22M | 61.71M | |
| P/E ratio | -0.47 | -5.28 | -0.39 | -1.3 | -1.02 | |
| Price to sales ratio | 1.81 | 9.55 | 1.68 | 3.38 | 2.45 | |
| POCF ratio | -3.34 | -8.43 | -2.51 | -4.72 | -5.75 | |
| PFCF ratio | -3.34 | -8.45 | -2.49 | -4.71 | -5.73 | |
| P/B Ratio | 1.06 | 7.68 | 0.62 | 1.7 | 1.45 | |
| PTB ratio | 1.06 | 7.68 | 0.62 | 1.7 | 1.45 | |
| EV to sales | 3.77 | 11.93 | 2.82 | 5.47 | 5.16 | |
| Enterprise value over EBITDA | -6.1 | -31.61 | -3.44 | -13.24 | -10.12 | |
| EV to operating cash flow | -6.98 | -10.52 | -4.21 | -7.62 | -12.11 | |
| EV to free cash flow | -6.97 | -10.55 | -4.17 | -7.61 | -12.07 | |
| Earnings yield | -0.53 | -0.05 | -0.64 | -0.19 | -0.25 | |
| Free cash flow yield | -0.3 | -0.12 | -0.4 | -0.21 | -0.17 | |
| Debt to equity | 1.85 | 2.31 | 1.16 | 1.64 | 2.15 | |
| Debt to assets | 0.48 | 0.58 | 0.46 | 0.55 | 0.6 | |
| Net debt to EBITDA | -3.18 | -6.29 | -1.39 | -5.05 | -5.32 | |
| Current ratio | 2.14 | 2.53 | 3.21 | 2.55 | 1.88 | |
| Interest coverage | -12.2 | -5.06 | -9.65 | -6.78 | 5.2 | |
| Income quality | 0.6 | 2.51 | 0.74 | 1.11 | 0.71 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.49 | 0.12 | 0.43 | 0.32 | 0.35 | |
| Research and developement to revenue | 0.12 | 0.11 | 0.14 | 0.11 | 0.12 | |
| Intangibles to total assets | 0.34 | 0.39 | 0.29 | 0.29 | 0.31 | |
| Capex to operating cash flow | 0 | 0 | 0.01 | 0 | 0 | |
| Capex to revenue | 0 | 0 | -0.01 | 0 | 0 | |
| Capex to depreciation | 0 | 0.01 | -0.03 | -0.01 | -0.01 | |
| Stock based compensation to revenue | 0.16 | 0.13 | 0.1 | 0.08 | 0.07 | |
| Graham number | 53.66 | 1.66 | 21.24 | 8.14 | 6.45 | |
| ROIC | -0.18 | -0.09 | -0.17 | -0.1 | -0.09 | |
| Return on tangible assets | -0.22 | -0.15 | -0.22 | -0.15 | -0.14 | |
| Graham Net | -23.47 | -1.05 | -2.45 | -2.5 | -3 | |
| Working capital | 26.2M | 21.84M | 37.27M | 28M | 18.75M | |
| Tangible asset value | -7.35M | -9.6M | 9.34M | 3.34M | -2.07M | |
| Net current asset value | -13.07M | -15.6M | 3.01M | -6.63M | -12.53M | |
| Invested capital | 1.85 | 2.31 | 1.16 | 1.64 | 2.15 | |
| Average receivables | 6.9M | 7.02M | 7.32M | 7.67M | 7.76M | |
| Average payables | 3.05M | 2.81M | 3.25M | 3.75M | 3.43M | |
| Average inventory | 16.97M | 16.93M | 17.02M | 17.54M | 18.03M | |
| Days sales outstanding | 48.55 | 47.23 | 53.08 | 53.4 | 56.93 | |
| Days payables outstanding | 43.98 | 39.23 | 60.18 | 57.39 | 47.54 | |
| Days of inventory on hand | 264.98 | 235.74 | 280.45 | 268.71 | 284.75 | |
| Receivables turnover | 1.85 | 1.91 | 1.7 | 1.69 | 1.58 | |
| Payables turnover | 2.05 | 2.29 | 1.5 | 1.57 | 1.89 | |
| Inventory turnover | 0.34 | 0.38 | 0.32 | 0.33 | 0.32 | |
| ROE | -0.56 | -0.36 | -0.39 | -0.33 | -0.35 | |
| Capex per share | 0 | 0 | -0.02 | 0 | 0 |
UTRS Frequently Asked Questions
What is Minerva Surgical, Inc. stock symbol ?
Minerva Surgical, Inc. is a US stock , located in Santa clara of Ca and trading under the symbol UTRS
What is Minerva Surgical, Inc. stock quote today ?
Minerva Surgical, Inc. stock price is $0.46 today.
Is Minerva Surgical, Inc. stock public?
Yes, Minerva Surgical, Inc. is a publicly traded company.
Company Profile
- Volume Average 2.72K
- Market Capitalization 5.77M
- Employee 174
- CEO Mr. Todd Usen
- Headquarters Santa Clara,CA,US
- IPO Date 2021-10-22
-
Website
https://minervasurgical.com 
Minerva Surgical, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company offers Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps. Its devices are utilized by obstetrician-gynecologists in various medical treatment settings, including hospitals, ambulatory surgical centers, and physician offices. The company was incorporated in 2008 and is headquartered in Santa Clara, California.
